

CORRECTED VERSION

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2014/059199 A8

(43) International Publication Date
17 April 2014 (17.04.2014)

(51) International Patent Classification:

A61K 31/50 (2006.01) *A61K 31/7042* (2006.01)
A61K 31/19 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:

PCT/US2013/064418

(22) International Filing Date:

11 October 2013 (11.10.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/712,853 12 October 2012 (12.10.2012) US
13/713,031 13 December 2012 (13.12.2012) US

(71) Applicant: **VISION GLOBAL HOLDINGS LTD.**
[CN/CN]; Flat 2301, 23/f Fu Fai Commercial Centre, 27
Hillier Street, Sheung Wan, Hong Kong (CN).

(72) Inventors: **WONG, Bing Lou**; 3592 S. Mall Street, Irvine,
CA 92606 (US). **WAI, Norman Fung Man**; 3906 West
19th Ave, Vancouver, BC V6S 1E1 (CA). **KWOK, Sui
Yi**; Flat 2907, 29/f, Pik Wai House, Shek Pai Wan Estate,
Aberdeen, Hong Kong (CN). **LAU, Sze Hang**; Block B,
3/f, 3, Lau Li Street, North Point, Hong Kong (CN).

(74) Agent: **YIP, Sam T.**; Ella Cheong (Hong Kong) Limited,
5001 Hopewell Centre, 183 Queen's Road East, Wan Chai,
Hong Kong (CN).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,
BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR,

KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM,
ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:

30 May 2014

(15) Information about Correction:

see Notice of 30 May 2014

(54) Title: HEMOGLOBIN-BASED OXYGEN CARRIER-CONTAINING PHARMACEUTICAL COMPOSITION FOR CANCER TARGETING TREATMENT AND PREVENTION OF CANCER RECURRENCE

(57) Abstract: The present invention provides a pharmaceutical composition containing a hemoglobin-based oxygen carrier for treating cancer, preventing recurrence and metastasis of cancerous tumor. The composition can be used alone or in combination with at least one chemotherapeutic agent such as 5FU, Bortezomib, doxorubicin, cisplatin, or any combination thereof. The hemoglobin-based oxygen carrier in the composition is capable of targeting a surface receptor expressed on cancerous cells and facilitating the uptake of both hemoglobin-based oxygen carrier and the chemotherapeutic agent by the cancerous cells via a receptor-mediated mechanism. The hemoglobin-based oxygen carrier inhibits the expression of hypoxic response elements such as HIF1 α , VEGF, ET1, VHL, etc. The pharmaceutical composition of the present invention is also useful for inducing the apoptosis or cell death of a type of self-renewing and tumor-initiating cells called cancer stem cells which are located in the hypoxic niche of a cancerous tumor.



WO 2014/059199 A8